title: [Effective treatment of metastatic rhabdomyosarcoma with pazopanib].
abstract: Pazopanib, an oral tyrosine kinase inhibitor, is the first molecular-targeted agent approved for the treatment of advanced soft tissue sarcoma(STS). Rhabdomyosarcoma in adults is rare, accounting for less than 3%of all adult STS cases. A 57-year old woman presented with cervical lymphadenopathy. Computed tomography revealed a heterogeneous mass in the retroperitoneum, replacing the entire right kidney. On the basis of the above findings, the patient was diagnosed with alveolar rhabdomyosarcoma. She was first treated with 4 courses of vincristine, actinomycin D, and cyclophosphamide(VAC), which resulted in a partial response. Dose reduction and delay occurred owing to hematological toxicity and febrile neutropenia. As second-line chemotherapy, the patient was administered a single daily dose of 800 mg of pazopanib. Because of an episode of hand-foot syndrome and hepatic impairment, the 800-mg daily dose of pazopanib was reduced to a daily dose of 600 mg, which had to be further reduced to a daily dose of 400 mg owing to fatigue and anorexia. The patient maintained a partial response for a total of 4.3 months when treated with pazopanib. Therefore, this drug may be a new treatment option for patients showing metastatic STS after previous chemotherapy.
authors.affiliation: Dept. of Medical Oncology and Hematology, Sapporo Medical University School of Medicine.
authors.forename: Akari
authors.initials: A
authors.lastname: Hashimoto
authors.forename: Kohichi
authors.initials: K
authors.lastname: Takada
authors.forename: Rishu
authors.initials: R
authors.lastname: Takimoto
authors.forename: Hiroto
authors.initials: H
authors.lastname: Horiguchi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iyama
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Murase
authors.forename: Kaoru
authors.initials: K
authors.lastname: Ono
authors.forename: Ayumi
authors.initials: A
authors.lastname: Tatekoshi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Koji
authors.initials: K
authors.lastname: Miyanishi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sato
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kobune
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hirayama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitamura
authors.forename: Katsuya
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Naoya
authors.initials: N
authors.lastname: Masumori
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001707:Biopsy, Needle; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D011743:Pyrimidines / Q000627:therapeutic use*; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000556:secondary; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib